Rosiglitazone/metformin

Drug Profile

Rosiglitazone/metformin

Alternative Names: Avandamet; Avandamet XR; Rosicon-MF

Latest Information Update: 24 Mar 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator GlaxoSmithKline
  • Developer GlaxoSmithKline; Glenmark Pharmaceuticals Ltd
  • Class Antihyperglycaemics; Biguanides; Insulin sensitisers; Thiazolidinediones
  • Mechanism of Action AMP activated protein kinase stimulants; Peroxisome proliferator-activated receptor gamma agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Type 2 diabetes mellitus

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 18 May 2011 The US FDA places further restrictions on rosiglitazone-containing drugs
  • 08 Feb 2011 GlaxoSmithKline revises US prescription information for rosiglitazone-containing medicines
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top